Both in Biotechnology
Estrella Immunopharma vs Acumen Pharmaceuticals
Over the past year ESLA returned −80.6% and ABOS returned −88.9%; their daily moves had a correlation of 0.09.
ESLA −80.6% ABOS −88.9%Growth of $1, one year, split-adjusted
| Metric | ESLA | ABOS |
|---|---|---|
| Price | $0.4435 | $0.2163 |
| Market cap | $19.3M | $15.6M |
| Today | +6.10% | −7.72% |
| 1 month | +3.4% | −89.3% |
| 6 months | −65.9% | −91.6% |
| Year to date | −71.6% | −89.7% |
| 1 year | −85.5% | −90.1% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $146.7K | $52.3M |
| Dividend yield | — | — |
| Volatility (60d) | 201.6% | 492.9% |
| Short % of float | 4.0% | 7.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).